#####Manufacturing contracts from Nonavax and Eli Lilly
23 March 2021
Jubilant HollisterStier Announces COVID-19 Vaccine Candidate Manufacturing Agreement with Novavax
Jubilant HollisterStier LLC, a wholly owned subsidiary of Jubilant Pharma Limited, announced that it has entered into a non-exclusive manufacturing agreement with Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373. Under the terms of the agreement, Jubilant HollisterStier’s Spokane, Washington facility has begun production activities of NVX-CoV2373 final drug product intended for commercial distribution in the United States.
09 March 2021
Jubilant HollisterStier Signs Manufacturing Agreement with Eli Lilly for COVID-19 Therapeutic Bamlanivimab
Jubilant Life Sciences Ltd (“Jubilant”), an integrated global Pharmaceuticals and Life Sciences Company, recently announced that its wholly-owned subsidiary, Jubilant Pharma Limited, through one of its subsidiaries, Jubilant HollisterStier LLC (“Company”), has signed new contract with Eli Lilly for contract manufacturing of a treatment for COVID-19. The drug will be manufactured at the Spokane, Washington, USA facility of the Company.